Premium
Reduced Graphene Oxide@Mesoporous Silica–Doxorubicin/Hydroxyapatite Inorganic Nanocomposites: Preparation and pH–Light Dual‐Triggered Synergistic Chemo‐Photothermal Therapy
Author(s) -
Yang Ying,
Wang Yunlong,
Xu Wanghua,
Zhang Xiuzhen,
Shang Yong,
Xie Anjian,
Shen Yuhua
Publication year - 2017
Publication title -
european journal of inorganic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.667
H-Index - 136
eISSN - 1099-0682
pISSN - 1434-1948
DOI - 10.1002/ejic.201601487
Subject(s) - photothermal therapy , nanocomposite , graphene , chemistry , biocompatibility , doxorubicin , drug delivery , mesoporous silica , nanotechnology , oxide , photothermal effect , mesoporous material , materials science , organic chemistry , chemotherapy , catalysis , medicine , surgery
A new nanocomposite, reduced graphene oxide@mesoporous silica–doxorubicin/hydroxyapatite (rGO@mSiO 2 ‐DOX/HA), was prepared by a simple method under mild conditions. Owing to the relatively high loading capacity of the anticancer drug DOX, the biomimetic capping of nontoxic and pH‐dependent biodegradable HA on the surface of rGO@mSiO 2 ‐DOX, and the efficient photothermal conversion effect of rGO under near‐infrared (NIR) irradiation, the rGO@mSiO 2 ‐DOX/HA nanocomposite provides a lasting and pH–light dual‐triggered drug release. Therefore, the excellent biocompatibility and drug‐permeation ability of the nanocomposite are realized, and synergistic chemo‐photothermal therapy is also achieved. The in vitro experimental results indicate that the chemotherapy of DOX and hyperthermia of rGO under NIR light irradiation killed HeLa cells effectively. Therefore, the new nanocomposite has promising prospects as a nano‐drug‐delivery system and in other biomedical applications because of the pH–light dual‐factor sensitivity and chemo‐photothermal synergistic therapy.